Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone

Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone

Friedreich’s Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA.

Saved in:
Bibliographic Details
Published in:Degenerative neurological and neuromuscular disease Vol. 9; pp. 103 - 107
Main Authors: Ghanekar, Shaila D, Miller, Wai Wai, Meyer, Colin J, Fenelon, Kevin J, Lacdao, Alvin, Zesiewicz, Theresa A
Format: Journal Article
Language:English
Published: Macclesfield Dove Medical Press Limited 01-10-2019
Taylor & Francis Ltd
Dove
Subjects:
Age
Anopheles
Ataxia
Cardiomyopathy
Clinical trials
Diabetes
Dimethyl fumarate
Disease
Drug dosages
Drug therapy
Foot diseases
Genes
Health aspects
Heart
Metabolism
Myocardial diseases
Nervous system diseases
Neurodegeneration
Neurology
Orphan drugs
Oxidative stress
Pharmaceuticals
Product development
Review
Scoliosis
Varenicline
United States > US
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Friedreich’s Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1179-9900
1179-9900
DOI:10.2147/DNND.S180027